相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
Meaghan L. Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
Shaji K. Kumar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
Noopur Raje et al.
CLINICAL CANCER RESEARCH (2011)
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma
Stefan Wilop et al.
EPIGENETICS (2011)
Pomalidomide therapy for myeloma
Stephen Schey et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Acquired von Willebrand Syndrome Associated With Monoclonal Gammopathy A Single-Center Study of 36 Patients
Sophie Voisin et al.
MEDICINE (2011)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Anders Waage et al.
BLOOD (2010)
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
M. Lioznov et al.
BONE MARROW TRANSPLANTATION (2010)
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
A. K. Gandhi et al.
CURRENT CANCER DRUG TARGETS (2010)
Thromboembolic Complications in Malignant Haematological Disorders
Roberto Castelli et al.
CURRENT VASCULAR PHARMACOLOGY (2010)
Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression
Adel A. Guirgis et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease
Martin Perez-Andres et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
Angioedema due to acquired C1-inhibitor deficiency: A bridging condition between autoimmunity and lymphoproliferation
Massimo Cugno et al.
AUTOIMMUNITY REVIEWS (2008)
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
Tomer Mark et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
Matthew J. Streetly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
S. Vincent Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma
H. Paripati et al.
LEUKEMIA (2008)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I. Breitkreutz et al.
LEUKEMIA (2008)
Venous thromboembolic events and erythropoiesis-stimulating agents: An update
Mario Dicato
ONCOLOGIST (2008)
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients
A. Mazumder et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
Martha Q. Lacy et al.
MAYO CLINIC PROCEEDINGS (2007)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
S. Kumar et al.
LEUKEMIA (2007)
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
K. Zervas et al.
ANNALS OF ONCOLOGY (2007)
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57*cytotoxic T cells as predictors of outcome
Linda Mileshkin et al.
HAEMATOLOGICA (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells
Mostafa Jarahian et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells:: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens
Craig T. Morita et al.
IMMUNOLOGICAL REVIEWS (2007)
The evolving role of lenalidomide in the treatment of hematologic malignancies
Efstathios Kastritis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
M. Wang et al.
HEMATOLOGY (2007)
Adverse effects on hemostatic function of drugs used in hematologic malignancies
Anaadriana Zakarija et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
R. Baz et al.
ANNALS OF ONCOLOGY (2006)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Lenalidomide in multiple myeloma
Paul G. Richardson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Merkel cell carcinoma and multiple primary cancers
Regan A. Howard et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
Marc Beyer et al.
BLOOD (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma
MK Brimnes et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
M Cavo et al.
BLOOD (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
T Hayashi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC)
M Mohty et al.
BONE MARROW TRANSPLANTATION (2005)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner
F Payvandi et al.
CELLULAR IMMUNOLOGY (2004)
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant
AK Stewart et al.
CLINICAL CANCER RESEARCH (2004)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
Detection and activation of human Vα24+ natural killer T cells using α-galactosyl ceramide-pulsed dendritic cells
S Fujii et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K Dredge et al.
BRITISH JOURNAL OF CANCER (2002)
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy
M Cavo et al.
BLOOD (2002)
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
M Ratta et al.
BLOOD (2002)
Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10
RD Brown et al.
BLOOD (2001)
Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms
C Dong et al.
BRITISH JOURNAL OF CANCER (2001)
NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling
S Kreuz et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Biosynthesis and processing of cathepsin K in cultured human osteoclasts
DJ Rieman et al.
BONE (2001)
分享论文
